- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07693088
Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD): An Open-label Pilot Study
This open-label pilot study will evaluate the feasibility, safety, tolerability, and preliminary clinical outcomes of adding intermittent theta-burst stimulation (iTBS) to Eye Movement Desensitization and Reprocessing (EMDR) therapy in adults with post-traumatic stress disorder (PTSD), who show insufficient improvement after an initial course of EMDR.
Participants will receive weekly EMDR therapy. After seven EMDR sessions, treatment response will be assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response will receive add-on iTBS targeted to the right dorsolateral prefrontal cortex (DLPFC) for four weeks while continuing EMDR. Feasibility outcomes include adherence, treatment completion, and dropout rates. Clinical outcomes will include clinician-rated and self-reported measures of PTSD symptoms, depressive symptoms, well-being, and adverse events.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.
Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.
The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.
Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.
The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.
The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Pernille Kølbæk, MD PhD
- Telefonnummer: 004561397432
- E-Mail: perpet@rm.dk
Studieren Sie die Kontaktsicherung
- Name: Ana Lisa Carmo, Psychiatrist
- Telefonnummer: 0045 61155056
- E-Mail: ANAMAR@rm.dk
Studienorte
-
-
-
Aarhus N, Dänemark
- Aarhus University Hospital
-
Kontakt:
- Pernille Kølbæk, MD PhD
- Telefonnummer: 004561397432
- E-Mail: perpet@rm.dk
-
Kontakt:
- Ana Lisa Carmo, Psychiatrist
- Telefonnummer: 0045 61155056
- E-Mail: ANAMAR@rm.dk
-
Hauptermittler:
- Ana Lisa Carmo, Psychiatrist
-
Horsens, Dänemark
- Regional Psychiatry Horsens
-
Kontakt:
- Pernille Kølbæk, MD PhD
- Telefonnummer: 004561397432
- E-Mail: perpet@rm.dk
-
Kontakt:
- Thea Grønfeldt, Psychiatrist
- Telefonnummer: 00457847 9258
- E-Mail: theafaer@rm.dk
-
Hauptermittler:
- Pernille Kølbæk, MD PhD
-
Viborg, Dänemark
- Regional Psychiatry Central Jutland
-
Kontakt:
- Pernille Kølbæk, MD PhD
- Telefonnummer: 004561397432
- E-Mail: perpet@rm.dk
-
Hauptermittler:
- Ana Lisa Carmo, Psychiatrist
-
Kontakt:
- Ana Lisa Carmo, Psychiatrist
- Telefonnummer: 004561155056
- E-Mail: ANAMAR@rm.dk
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age 18-70 years
- ICD-10 criteria for PTSD (F43.1)
- A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S)
- Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment
- Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist.
Exclusion Criteria:
- Organic mental disorders (F0)
- Currently fulfills the criteria of Active psychoactive substance use or dependence (F1)
- Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ <70, as per the referring doctor's or psychologist's assessment)
- Active suicidality
- Any ongoing involuntary/coercive measures
- Any contraindications listed on the TMS Safety Checklist
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: EMDR with add-on iTBS
Participants receive weekly Eye Movement Desensitization and Reprocessing (EMDR) therapy for up to 16 weeks.
After seven EMDR sessions, treatment response is assessed using the Clinical Global Impression-Improvement scale (CGI-I).
Participants with insufficient response receive adjunctive intermittent theta-burst stimulation (iTBS) to the right dorsolateral prefrontal cortex for 20 sessions over 4 weeks while continuing EMDR.
Participants with sufficient response continue EMDR treatment alone.
|
All enrolled participants begin standardized EMDR treatment.
Participants who show insufficient clinical improvement after seven EMDR sessions receive adjunctive intermittent theta-burst stimulation (iTBS) while continuing EMDR.
Participants who show sufficient improvement continue EMDR alone.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Drop-out
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The primary outcome will be drop-out rates
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Treatment completion rates
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The second primary outcome will be treatment completion rates (number of iTBS treatments received out of the planned 20 treatments)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Symptom trajectories
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the PTSD Checklist for DSM-5 (PCL-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by International Trauma Questionnaire (ITQ)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the 6-item self-reported Hamilton Depression Rating Scale (HAM-D6-SR)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Transcranial Magnetic Stimulation Sensory Questionnaire (TMSens_Q)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
Zeitfenster: Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Aarhus Side Effects Assessment Scale (ASAQ)
|
Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Changes in mental well-being
Zeitfenster: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Mental well-being as measured by the World Health Organization 5-item well-being scale (WHO-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Pernille Kølbæk, Aarhus University Hospital
- Hauptermittler: Ana Lisa Carmo, Aarhus University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2502681
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .